EANS-Adhoc: Sartorius AG / Preliminary Figures for the First Nine Months of 2011

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

20.10.2011

Group sales revenue rises 12.2% to EUR541.4 million | Underlying
EBITA soared 38.3% to EUR81.5; the respective margin improves to
15.0% | Management raises full-year guidance for sales revenue

In the first nine months of 2011, order intake for the Sartorius
Group increased 8.5% (currency-adjusted: +10.0%) from EUR508.3
million to EUR551.3 million. Its sales revenue rose 12.2%
(currency-adj.: +13.8%) to EUR541.4 million from EUR482.3 a year ago.
The Biotechnology Division achieved an order intake of EUR365.7
million, up 10.5% (currency-adj.: +12.4%) from EUR330.9 million a
year earlier, and boosted its sales revenue year on year by 10.9%
(currency-adj.: +12.6%) to EUR353.5 million from EUR318.8 million.
For the Mechatronics Division, order intake was up 4.6%
(currency-adj.: +5.6%), to EUR185.7 million from EUR177.4 million);
the division´s sales revenue grew 14.9% (currency-adj. +16.0%) to
EUR187.9 million from EUR163.6 million in the previous year.

Underlying EBITA surged from EUR58.9 million to EUR81.5 million; this
reflects earnings before interest, taxes and amortization and is
adjusted for extraordinary items of -EUR7.7 million (prev. yr.:
-EUR3.3 million). The respective margin jumped from 12.2% to 15.0%.
The Biotechnology Division contributed an underlying EBITA of EUR60.9
million, up from EUR50.1 million a year ago. Its margin increased
accordingly from 15.7% to 17.2%. The Mechatronics Division more than
doubled its contribution to earnings, from EUR8.8 million to EUR20.6
million; its earnings margin climbed from 5.4% to 10.9%.

Excluding non-cash amortization, underlying net profit after
non-controlling interest for the nine-month period totaled EUR38.0
million, up from EUR26.4 million a year earlier; the respective
earnings per share were at EUR2.23, up from EUR1.55 a year ago.

Based on the Group´s strong business performance, management has
again revised its full-year 2011 guidance slightly upward: Sales in
constant currencies are projected to grow for both divisions and thus
also for the Group between 10% and 11% (former guidance: 8% to 10%).
Earnings guidance is confirmed both for the two divisions and for the
Group. Management therefore continues to expect that the
Biotechnology Division and the Mechatronics Division will achieve an
underlying EBITA margin of 17% to 18% and of 10% to 11% in constant
currencies, respectively. At Group level, guidance remains unchanged
for the operating EBITA margin, which is forecasted to improve to
between 14.5% and 15.5%. Moreover, management continues to expect
that operating cash flow will be significantly positive in 2011.

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of the
Sartorius Group, will discuss the results with analysts and investors
on Friday, October 21, 2011, at 3:30 p.m. Central European Time in a
webcast teleconference. You may dial into the teleconference starting
at 3:15 p.m. CET at the following numbers: Germany +49 (0)69 2999
3285; France +33(0)1 70 48 01 63; UK +44(0)20 7660 0009; USA +1 646
254 3375. The dial-in code is as follows: 3684539 The webcast and
presentation can be viewed at www.sartorius.de.

Goettingen, October 20, 2011

Further inquiry note:
Andreas Theisen

Phone +49(0) 551.308.1668
Fax +49(0)551.308.3153
andreas.theisen@
sartorius.com
www.sartorius.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Sartorius AG
Weender Landstr. 94-108
D-37075 Göttingen
phone: +49 (0)551 308-0
FAX: +49 (0)551 308-3289
mail: info.investor@sartorius.com
WWW: http://www.sartorius.com
sector: Biotechnology
ISIN: DE0007165607, DE0007165631
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English